Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Pathol. 2008 Mar;61(3):307-10. Epub 2007 Jun 22.

EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder.

Author information

1
Institute of Pathology, Medical University of Innsbruck, Austria. andrea.brunner@i-med.ac.at

Abstract

BACKGROUND:

EpCAM is an adhesion molecule of the basolateral membranes in a variety of epithelial cells. Over-expression has been detected in many epithelial tumours and has been associated with high stage, high grade and a worse survival in some tumour types.

AIMS:

To assess the prognostic value of EpCAM in urothelial carcinoma of the bladder.

METHODS:

EpCAM expression was analysed by immunohistochemistry using a monoclonal antibody (clone VU-1D9) on a tissue microarray comprising 99 urothelial carcinomas of the bladder diagnosed between 1994 and 1997.

RESULTS:

A significant relationship between high grade, advanced stage, and EpCAM expression was found, and expression of EpCAM was associated with a worse overall survival when compared to EpCAM negative tumours (p = 0.033). Multivariate analysis showed that EpCAM expression was not an independent prognostic factor for overall survival in urothelial carcinoma of the bladder.

CONCLUSION:

EpCAM expression is associated with advanced stage, high grade and poor overall survival in urothelial carcinoma of the bladder, but lacks an independent prognostic significance. The strong association with high grade tumours suggests a possible role during tumour progression and makes EpCAM a potential target for antibody mediated therapy.

PMID:
17586680
DOI:
10.1136/jcp.2007.049460
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center